Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Lifarizine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.43 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.43 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.43 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.43 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.43 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.43 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.43 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.43 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.43 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.43 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | DRD2 | P14416 | 2/20 | 0.50 |
| ▸ | DRD4 | P21917 | 2/20 | 0.50 |
| ▸ | DRD3 | P35462 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 3/20 | 0.45 |
| ▸ | CTSS | P25774 | 3/20 | 0.45 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lifarizine SCHEMBL676318 | 0.92 | DRD2 (0.57) | CYP3A4CYP2C19DRD2DRD4DRD3 | |
| Lifarizine SCHEMBL8963776 | 0.91 | DRD2 (0.56) | CYP3A4CYP2C19DRD2DRD4DRD3 | |
| SCHEMBL9424741 | 0.89 | DRD3 (0.55) | CYP3A4CYP2C19DRD2DRD4DRD3 | |
| SCHEMBL8963644 | 0.87 | DRD3 (0.56) | CYP3A4CYP2C19DRD2DRD4DRD3 | |
| SCHEMBL8964084 | 0.87 | DRD2 (0.52) | CYP3A4CYP2C19DRD2DRD4DRD3 | |
| SCHEMBL8963668 | 0.87 | DRD2 (0.64) | CYP3A4CYP2C19DRD2DRD4DRD3 | |
| SCHEMBL8963501 | 0.85 | CTSS (0.52) | CYP3A4CYP2C19DRD2DRD4DRD3 | |
| SCHEMBL8963661 | 0.83 | CYP3A4 (0.49) | CYP3A4CYP2C19DRD2DRD4DRD3 | |
| SCHEMBL8963974 | 0.83 | DRD3 (0.59) | CYP3A4CYP2C19DRD2DRD4DRD3 | |
| SCHEMBL8963806 | 0.83 | CYP3A4 (0.56) | CYP3A4CYP2C19DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0365363-B1 | Parenteral formulations of 1-diphenylmethyl-4-[(2-(4-methylphenyl)-5-methyl-1H-imidazol-4-yl)methyl]piperazine | SYNTEX PHARMACEUTICALS LTD. (GB) | 1993-04-14 | — | — | EP | disclosed |
| US-5063220-A | Strokes | SYNTEX PHARMACEUTICALS, LTD. (GB) | 1991-11-05 | — | — | US | disclosed |
| US-4973591-A | SALT FORMATION IN SITU, TREATMENT OF STROKES | SYNTEX PHARMACEUTICALS, LTD. (GB) | 1990-11-27 | — | — | US | disclosed |
| EP-0365363-A1 | Parenteral formulations of 1-diphenylmethyl-4-[(2-(4-methylphenyl)-5-methyl-1H-imidazol-4-yl)methyl]piperazine | SYNTEX PHARMACEUTICALS LTD. (GB) | 1990-04-25 | — | — | EP | disclosed |